| 研究課題/領域番号 |
15H05294
|
|---|
| 研究機関 | 筑波大学 |
|---|
研究代表者 |
河野 了 筑波大学, 医学医療系, 講師 (90323295)
|
|---|
| 研究分担者 |
下條 信威 筑波大学, 医学医療系, 講師 (20462210)
Jesmin Subrina 筑波大学, 体育系, 研究員 (60374261)
|
|---|
| 研究期間 (年度) |
2015-04-01 – 2018-03-31
|
| キーワード | 南アジア / 糖尿病 / メタボリック症候群 / ヒ素 / メカニズム |
|---|
| 研究実績の概要 |
Non-communicable disease (NCD) risk factors (behavioral, physical and biochemical) are more prevalent in arsenic exposed population than the non-arsenic population. In addition, the severity and prevalence of the NCD risk factors also depends on the duration of arsenic exposure. Average arsenic level of drinking water of these population is 0.267 mg/L. Among the behavioral risk factors, irregular dietary habit with less serving of fruits and vegetables are significantly higher in arsenic exposed population than in non-arsenic exposed population. BMI is higher in arsenic exposed population (24.02 ± 1.27) than in non-arsenic exposed people (22.4 ± 0.04). The prevalence of obesity in the population who are exposed to arsenic more than ten years is 13.16% which is almost double than the arsenic exposed people of less duration and this prevalence is more less in non-arsenic exposed population. Diabetes prevalence is higher in arsenic exposed population (13.8%) than in non-exposed population (10.1%). Hypertension prevalence is also higher in arsenic exposed population (34.5%) than in non-exposed people (25.3%). Percentage of metabolic syndrome is higher in arsenic exposed population (37.6%) than in non-arsenic exposed population (26%). Among various biomarkers, VEGF has been higher in arsenic exposed population than in non-arsenic exposed people. In addition, from case-control study, high prevalence of hypertension, high mean levels of cholesterol and triglyceride, low HDL level is observed in arsenic-DM population than in arsenic-non DM population.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
The current research is on the right track both from the contexts of time line and the amount of research activities scheduled to be done (100% done with target milestone achievement) with the proper management of project budget. Keeping consistency with original research application and planning, in first and 2nd year of this project, we already we performed the greater part of cross sectional study undertaken in rural Bangladesh to estimate the prevalence of NCD risk factors in arsenic exposed population in rural Bangladesh (almost done). In addition, we have also completed a major part of case-control study. We consistently collected drinking water, blood, urine, hair and nail samples of arsenic affected population in rural Bangladesh with also those samples from non-arsenic exposed population. We already completed the data entry and made statistical analysis of that cross sectional data. An in depth analysis on NCD risk factors prevalence in between arsenic exposed population and non-arsenic exposed people (country wide national representative data) was done. In addition, crucial biomarkers are also assessed in study samples. Analysis is on-going for the case control study now. Just a bit interruption was done for case control and cross sectional study due to flood disaster in Bangladesh.
|
| 今後の研究の推進方策 |
In the 3rd year of this project, we will continue a bit the cross sectional study in Bangladesh (350 samples left). We already started a case control study last year. We will also complete the case-control study this year. The rest part of a case control study will be performed on 50 diabetic arsenic contaminated and 50 age-matched arsenic contaminated populations in Bangladesh. We will also continue measuring arsenic concentration in blood, urine, hair and nail samples of study subjects. In this year also, a number of advanced biomarkers will be measured in blood sample of study subjects. Besides, data entry and associated analysis will be done simultaneously at the final form. Manuscripts will be prepared and submitted to high impact factor journal. The findings will be presented in International Diabetes Federation Western Pacific Region Congress (11th IDF-WPR Congress) in 2017. In 2017, we will perform gene polymorphism and xenobiotic analysis. Final data will be presented at Annual Congress of American Diabetes Association in 2018.
|
